172 results
Page 3 of 9
8-K
EX-99.1
srbkw02i06tco
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
xt1yw2h93r40yz
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
8-K
78e7mcstrwdo4 cath
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
8-K
EX-99.1
mf31qlcc
3 Oct 22
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
8:30am
8-K
EX-99.1
rc89djcod wyvt46c60
12 Aug 22
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:41am
424B5
gdyjdfzwfu
12 Aug 22
Prospectus supplement for primary offering
8:31am
8-K
6wy40tmqeioojxx0l
25 May 22
Regulation FD Disclosure
7:02am
8-K
EX-99.1
0hjaj
12 May 22
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:40pm
8-K
EX-1.1
xykck
13 Apr 22
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
4:26pm
424B5
farfatby2evd77kfp 3u
13 Apr 22
Prospectus supplement for primary offering
4:22pm
S-8
co3pnkn
30 Mar 22
Registration of securities for employees
7:07pm
S-8
sb4hpf2tab
30 Mar 22
Registration of securities for employees
7:07pm
S-8
EX-5.1
0egseyk744oqzn
30 Mar 22
Registration of securities for employees
7:07pm